Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Mon, 16.08.2021
CureVac
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA backbone
Data demonstr [ … ]
Wed, 30.06.2021
CureVac
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
- Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for efficacy analysis; original strain almost completely absent
- Statistical s [ … ]
Wed, 30.06.2021
CureVac
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)TÜBINGEN, Germany / BOSTON, USA - June 30, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medici [ … ]
Thu, 24.06.2021
CureVac
CureVac Announces Voting Results of General MeetingTÜBINGEN, Germany / BOSTON, USA - June 24, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meetin [ … ]
Wed, 23.06.2021
CureVac
CureVac Provides Supervisory Board UpdateTÜBINGEN, Germany / BOSTON, USA - June 23, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Dr. Ingmar Hoerr, former Founding-CEO and former member of the [ … ]
Wed, 16.06.2021
CureVac
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
- Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent
- At second interim analysis, statistical success criteria not met. Favorable safety profile con [ … ]
Wed, 02.06.2021
CureVac
CureVac Appoints Klaus Edvardsen as Chief Development OfficerTÜBINGEN, Germany / BOSTON, USA - June 2, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Klaus Edvardsen, MD, PhD, as [ … ]
Fri, 28.05.2021
CureVac
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
- Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases
- Sequencing data to be made available in parallel with efficacy da [ … ]
Wed, 26.05.2021
CureVac
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
- First-Generation COVID-19 vaccine program, CVnCoV
- Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities
- Phase 2a trial in Peru and Panama assessing third booster vaccination at one and six month post second dose
- CureVac p [ … ]
Thu, 13.05.2021
CureVac
Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK
- CV2CoV mRNA shows high levels of antigen production in rat model
- Fast onset of strong neutralizing antibo [ … ]